Pregabalin
- Generic Name
- Pregabalin
- Brand Names
- Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H17NO2
- CAS Number
- 148553-50-8
- Unique Ingredient Identifier
- 55JG375S6M
- Background
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels. Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release). It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.
- Indication
Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.
- Associated Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
- Associated Therapies
- -
A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2021-01-25
- Target Recruit Count
- 751
- Registration Number
- NCT00645398
- Locations
- 🇺🇸
Pfizer Investigational Site, Yakima, Washington, United States
GABA (Gamma Amino Butyric Acid) Medication for Tobacco
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Yale University
- Target Recruit Count
- 24
- Registration Number
- NCT00644137
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)
- Conditions
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 421
- Registration Number
- NCT00643760
- Locations
- 🇺🇸
GSK Investigational Site, Vancouver, Washington, United States
A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures
- Conditions
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT00643136
- Locations
- 🇳🇱
Pfizer Investigational Site, Heeze, Netherlands
Lumbar Stenosis Outcomes Research (LUSTOR)
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2016-06-20
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 29
- Registration Number
- NCT00638443
- Locations
- 🇺🇸
2180 South Clinton Avenue, Rochester, New York, United States
Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Associazione Progetto Oncologia UMAN.A
- Target Recruit Count
- 80
- Registration Number
- NCT00637975
- Locations
- 🇮🇹
Ospedale Sacro Cuore, Negrar, Verona, Italy
🇮🇹Ospedali Riuniti, Bergamo, Italy
🇮🇹Ospedale S. Orsola, Brescia, Italy
Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2021-01-26
- Target Recruit Count
- 222
- Registration Number
- NCT00631696
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Dr Andrea Rossetti
- Target Recruit Count
- 52
- Registration Number
- NCT00629889
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭USZ, Zürich, Switzerland
A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2021-01-25
- Target Recruit Count
- 217
- Registration Number
- NCT00629681
- Locations
- 🇩🇪
Pfizer Investigational Site, Zwoenitz, Germany
Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2021-01-28
- Target Recruit Count
- 615
- Registration Number
- NCT00624780
- Locations
- 🇹🇷
Pfizer Investigational Site, Kocaeli, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.